Dr. med. Maike Holtsche

1. Holtsche MM, van Beek N, Hashimoto T, Di Zenzo G, Zillikens D, Prost-Squarcioni C, Titeux M, Hovnanian A, Schmidt E, Goletz S. Diagnosis of epidermolysis bullosa acquisita: Multicenter comparison of different assays for serum anti-type VII collagen reactivity. Acta Derm Venereol 2021;101(3):adv00420

2. van Beek N, Weidinger A, Schneider SW, Kleinheinz A, Gläser R, Holtsche MM, von Georg A, Hammers CM, Hübner F, Lima AL, Gola D, Sadik CD, Zillikens D, Katalinic A, Schmidt E, König IR. Incidence of pemphigoid diseases in Northern Germany in 2016 - first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases. J Eur Acad Dermatol Venereol 2021;35(5):1197-1202

3. Holtsche MM, van Beek N, Künstner A, Busch H, Zillikens D, Schmidt E. Diagnostic value and practicability of serration pattern analysis by direct immunofluorescence microscopy in pemphigoid diseases. Acta Derm Venereol 2021;101(3):adv00410

4. Holtsche MM, Goletz S, von Georg A, van Beek N, Hübner F, Pigors M, Zillikens D, Schmidt E. Serologic characterization of anti-p200 pemphigoid: Epitope spreading as a common phenomenon. J Am Acad Dermatol 2021;84(4):1155-1157

5. Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM, Schmidt E, Meshrkey F, Mousavi S, Zillikens D, Nunn MA, Sadik CD. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight 2019;4:e128239

6. Russlies J, Fähnrich A, Witte M, Yin J, Benoit S, Gläser R, Günter C, Eming R, Erdmann J, Gola D, Gupta Y, Holtsche MM, Kern JS, König IR, Kiritsi D, Lieb W, Sadik CD, Sárdy M, Schauer F, van Beek N, Weidinger A, Worm M, Zillikens D, Schmidt E, Busch H, Ibrahim SM, Hirose M. Polymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans. Front Immunol 2019; 10:2200

7. Chakievska L, Holtsche MM, Kunstner A, Goletz S, Petersen BS, Thaci D, Ibrahim SM, Ludwig RJ, Franke A, Sadik CD, Zillikens D, Holscher C, Busch H, Schmidt E. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun 2019; 96:104-112

8. Kasprick A, Holtsche MM, Rose EL, Hussain S, Schmidt E, Petersen F, Panicker S, Ludwig RJ. The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies. J Invest Dermatol 2018; 138:458-461

9. Karsten CM, Beckmann T, Holtsche MM, Tillmann J, Tofern S, Schulze FS, Heppe EN, Ludwig RJ, Zillikens D, König IR, Köhl J, Schmidt E. Tissue destruction in bullous

pemphigoid can be complement independent and is mitigated by C5aR2. Front Immunol 2018; 9:488

10. Holtsche MM, Goletz S, van Beek N, Zillikens D, Benoit S, Harman K, Walton S., English J, Sticherling M, Chapman A, Levell NJ, Groves R, Williams HC, König IR, Schmidt E and members of the BLISTER Study Group*. Prospective study in bullous pemphigoid: Association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score. Br J Dermatol 2018; 179:918-924